.png){kind=icon}
返回
.png){kind=icon}
.png){kind=icon}
摘要
En 中文
Saxagliptin and its active metabolite M2 are dipeptidyl peptidase-4 inhibitors that improve glycaemic control by preventing the inactivation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide. This increases GLP-1 levels, stimulates insulin secretion and reduces postprandial glucagon and glucose levels. In well designed, 24-week trials in treatmentnaive patients with type 2 diabetes mellitus, monotherapy with oral saxagliptin 2.5 or 5 mg once daily significantly improved glycaemic control, as measured by mean glycosylated haemoglobin (HbA(1c)) levels, relative to placebo. In large, well designed, 24-week trials, combination therapy with saxagliptin 5 mg once daily plus metformin significantly improved HbA(1c) levels relative to single-agent saxagliptin or metformin in treatment-naive patients; in treatment-experienced patients with inadequate glycaemic control, the addition of saxagliptin 2.5 or 5 mg once daily to metformin, glyburide or a thiazolidinedione, significantly improved HbA(1c) levels relative to continued use of existing monotherapy. Saxagliptin as monotherapy or in combination with other oral antihyperglycaemics was generally well tolerated, with most adverse events being of mild to moderate severity. In clinical trials, the incidence of hypoglycaemic events in patients receiving saxagliptin was generally similar to that in patients receiving placebo or other oral antihyperglycaemic agents. Saxagliptin therapy was not associated with an increased risk of cardiovascular events according to pooled data from eight clinical trials. Saxagliptin generally had a weight-neutral effect.
Keyword:
IMPROVES GLYCEMIC CONTROL
SINGLE-DOSE PHARMACOKINETICS
INHIBITOR SAXAGLIPTIN
SAXGALIPTIN
METFORMIN
THERAPY
SAFETY
SULFONYLUREA
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
引用论文
New drugs for the treatment of diabetes - Part II: Incretin-based therapy and beyond.png)
CIRCULATION.png)
OAAI
CIRCULATIONIF38.6
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏
分享收藏The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin AloneDIABETES CAREOAAI
DIABETES CAREIF16.6
OAAI分享收藏Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes2型糖尿病高血糖的医学管理: 启动和调整治疗的共识算法美国糖尿病协会和欧洲糖尿病研究协会的共识声明DIABETES CAREOAAI
DIABETES CAREIF16.6
OAAI分享收藏
查看更多内容